A smartphone-assisted pressure-measuring-based diagnosis system for acute myocardial infarction diagnosis

Guolin Hong1 Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Gang Rui2 Department of Orthopaedic Surgery, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Dongdong Zhang1 Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Mingjian Lian1 Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Yuanyuan Yang1 Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Ping Chen1 Department of Laboratory Medicine, The First Affiliated Hospital of Xiamen University, Xiamen 361005, People’s Republic of China

Huijing Yang3 Department of Clinical Medicine, Fujian Medical University, Fuzhou 350108, People’s Republic of China

Zhichao Guan4 Department of Research and development, Xiamen Passtech Co.,Ltd., Xiamen 361101, People’s Republic of China

Wei Chen5 Higher Educational Key Laboratory for Nano Biomedical Technology of Fujian Province, Department of Pharmaceutical Analysis, Fujian Medical University, Fuzhou 350004, People’s Republic of China, [email protected]Correspondence[email protected]

Yan Wang6 Department of Cardiology, the Affiliated Cardiovascular Hospital of Xiamen University, Medical College of Xiamen University, Xiamen 361004, People’s Republic of China, [email protected]Correspondence[email protected]

show all

Abstract

Background

Acute myocardial infarction (AMI), usually caused by atherosclerosis of coronary artery, is the most severe manifestation of coronary artery disease which results in a large amount of death annually. A new diagnosis approach with high accuracy, reliability and low measuring-time-consuming is essential for AMI quick diagnosis.

Purpose

The objective of this study was to develop a new point-of-care testing system with high accuracy and reliability for AMI quick diagnosis.

Patients and methods

50 plasma samples of acute myocardial infarction patients were analyzed by developed Smartphone-Assisted Pressure-Measuring-Based Diagnosis System (SPDS). The concentration of substrate was firstly optimized. The effect of antibody labeling and matrix solution on measuring result were then evaluated. And standard curves for cTnI, CK-MB and Myo were built for clinical sample analysis. The measuring results of 50 clinical samples were finally evaluated by comparing with the measuring result obtained by CLIA.

Results

The concentration of substrate H₂O₂ was firstly optimized as 30% to increase measuring signal. A commercial serum matrix was chosen as the matrix solution to dilute biomarkers for standard curve building to minimize matrix effect on the accuracy of clinical plasma sample measuring. The standard curves for cTnI, CK-MB and Myo were built, with measuring dynamic range of 0–25 ng/mL, 0–33 ng/mL and 0–250 ng/mL, and limit of detection of 0.014 ng/mL, 0.16 ng/mL and 0.85 ng/mL respectively. The measuring results obtained by the developed system of 50 clinical plasma samples for three biomarkers matched well with the results obtained by chemiluminescent immunoassay.

Conclusion

Due to its small device size, high sensitivity and accuracy, SPDS showed a bright potential for point-of-care testing (POCT) applications.

Keywords:

Supplementary materials

Figure S1 Optimization result of H₂O₂ concentration.

Figure S1 Optimization result of H2O2 concentration.

Figure S2 The nanoparticle zeta-average diameter profile of PtNPs before labeling (A) and after labeling for cTnI (B), CK-MB (C), and Myo (D).

Abbreviations: PtNPs, platinum nanoparticles; cTnI, cardiac troponin I; CK-MB, MB isoenzyme of creatine kinase; Myo, myoglobin.

Figure S3 Linearly fitting results for cTnI (A), CK-MB (B), and Myo (C) under low concentrations.

Abbreviations: cTnI, cardiac troponin I; CK-MB, MB isoenzyme of creatine kinase; Myo, myoglobin.

Acknowledgments

We gratefully acknowledge the financial support from the National Natural Science Foundation of China (81772287, 81371902), the Natural Science Foundation of Fujian Province of China (2016J01643), and the Joint Project of Major Diseases in Xiamen City of China (3502Z20179044).

Disclosure

The authors report no conflicts of interest in this work.